Más sobre las estatinas

Más sobre las estatinas

En este estudio publicado en la revista Tórax se enfatiza que el EPOC de moderado a grave se asocia con mayor tasa de mortalidad por cáncer de pulmón y el EPOC moderado se asocia con mayor tasa de mortalidad por cáncer de extrapulmonar y en el mismo se ha encontrado que el uso de estatinas en los pacientes con EPOC se asocia con un riesgo reducido de cáncer extrapulmonar

Published Online First: 30 August 2009. doi:10.1136/thx.2009.116731

Thorax 2009;64:963-967

Copyright © 2009 BMJ Publishing Group Ltd & British Thoracic Society.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

COPD and cancer mortality: the influence of statins

Y R B M van Gestel1, S E Hoeks1, D D Sin2, V Hüzeir3, H Stam4, F W Mertens4, R T van Domburg3, J J Bax5, D Poldermans1

1 Department of Anaesthesiology, Erasmus Medical Centre, Rotterdam, The Netherlands

2 Department of Medicine, University of British Columbia and The James Hogg iCAPTURE Centre, St Paul’s Hospital, Vancouver, Canada

3 Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands

4 Department of Pulmonology, Erasmus Medical Centre, Rotterdam, The Netherlands

5 Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands

Correspondence to Professor D Poldermans, Erasmus Medical Centre Rotterdam, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands; d.poldermans@erasmusmc.nl

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of lung cancer, independently of smoking. However, the relationship between COPD and total cancer mortality is less certain. A study was undertaken to investigate the association between COPD and total cancer mortality and to determine whether the use of statins, which have been associated with cancer risk in other settings, modified this relationship.

Methods: The study included 3371 patients with peripheral arterial disease who underwent vascular surgery between 1990 and 2006; 1310 (39%) had COPD and the rest did not. The primary end point was cancer mortality (lung and extrapulmonary) over a median follow-up of 5 years.

Results: COPD was associated with an increased risk of both lung cancer mortality (hazard ratio (HR) 2.06; 95% CI 1.32 to 3.20) and extrapulmonary cancer mortality (HR 1.43; 95% CI 1.06 to 1.94). The excess risk was mostly driven by patients with moderate and severe COPD. There was a trend towards a lower risk of cancer mortality among patients with COPD who used statins compared with patients with COPD who did not use statins (HR 0.57; 95% CI 0.32 to 1.01). Interestingly, the risk of extrapulmonary cancer mortality was lower among statin users with COPD (HR 0.49; 95% CI 0.24 to 0.99).

Conclusions: COPD was associated with increased lung and extrapulmonary cancer mortality in this large cohort of patients with peripheral arterial disease undergoing vascular surgery. The risk of lung cancer mortality increased with progression of COPD. Statins were associated with a reduced risk of extrapulmonary cancer mortality in patients with COPD.